Results 211 to 220 of about 6,799 (258)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

Structural insights into the catalytic mechanism of the microcystin tailoring enzyme McyI. [PDF]

open access: yesCommun Biol
Wang X   +8 more
europepmc   +1 more source

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Using UK Biobank proteomic data, we identified a five‐protein score reflecting hepatic stellate cell activation and hepatocellular injury that predicts major adverse liver outcomes and clinically significant fibrosis, with consistent performance validated in two independent cohorts (patients with HIV and alpha1‐antitrypsin deficiency).
Sriram Balasubramani   +14 more
wiley   +1 more source

Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL‐AVA 3.5 study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA).
Caroline Piatek   +8 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Assessing Correlation of Quantitative Technetium‐99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone‐Induced Thyrotoxicosis

open access: yes
Journal of Medical Imaging and Radiation Oncology, EarlyView.
Ray Wang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy